Interview with Piero Di Lorenzo. Anti-Covid vaccine in November, then the stock market listing: these are Mr. Vaccine’s goals.

Comments (0)

[vc_row][vc_column][vc_column_text css=”.vc_custom_1601365521343{margin-bottom: 30px !important;}”]Il Riformista logo

Stock market could be in the future of IRBM, the Italian company that collaborates in the vaccine development with the Jenner Institute of Oxford and the British pharmaceutical company AstraZeneca. The President of IRBM, Piero Di Lorenzo, admits: «We receive many partnership proposals, several big companies would like to buy the shares. Many people are interested in us all over the world, I don’t rule out any option». But there is no time to consider this opportunity until the vaccine is validated. Di Lorenzo talks about the clinical trials currently ongoing, pointing out that while technical times have been shortened, those of experimentation continue to be respected.

Article by Riccardo Amati published on Il Riformista28/09/2020

Download pdf[/vc_column_text][/vc_column][/vc_row]

Comments are closed.